USCOM LIMITED — Investor Presentation 2015

Aug 31, 2015

==> picture [88 x 98] intentionally omitted <==

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the accompanying Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

2

Uscom

Products generate profit

High growth (+50%), innovative medical device company Poised for strategic growth with recent acquisitions Valuable IP with high margins (75+%) Targeting key cardiovascular markets with multiple products Undervalued - $15m market cap US growth from new products Fundamentals to drive value

==> picture [37 x 44] intentionally omitted <==

3

==> picture [687 x 386] intentionally omitted <==

USCOM helps to save baby's life in Nottingham https://youtu.be/bJXx5nmUeF8

==> picture [37 x 44] intentionally omitted <==

3

Uscom Vision

Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards

“A milestone driven global medical device company with real products, real revenue, real growth and an aggressive growth strategy”

==> picture [368 x 47] intentionally omitted <==

==> picture [204 x 90] intentionally omitted <==

5

Current Business

• Premium noninvasive cardiovascular and pulmonary monitoring devices

• Addressing the growing threat of superbugs, heart failure, hypertension and asthma

• Validated, clinically accepted, cost and life saving devices

• Patent protected with regulatory approvals

• Uscom BP+ for market 2016 - $7m over 5years Chinese contract in place

• Rapidly growing revenues in major markets and new untouched markets

• Corporate Board & Management

• ASX listed (UCM)  Rob Phillips, Chairman & CEO  Headquartered in Sydney  Sheena Jack, Director  (HCF, Moneytime Health) Market cap of $15m

• 92m shares on issue  Christian Bernecker, Director (Stream)

• Rob Phillips, Founder and  Nick Schicht, General Manager

• CEO, holds 20% of company

• Financials

• Sales +58% 2015  Revenue +48% 2015 ($2+m)

• Cash consumption - $1m

• Gross Margins ~ 78%  Cash $2.5m

==> picture [37 x 44] intentionally omitted <==

6

• Uscom Annual report

Operational growth

==> picture [323 x 268] intentionally omitted <==

----- Start of picture text -----

Revenue and Income
$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015
----- End of picture text -----

==> picture [317 x 265] intentionally omitted <==

----- Start of picture text -----

Distribution Agreements
40 38
35
30
27
25
20
15
12
10
5
0
2013 2014 2015
----- End of picture text -----

Distribution – sales – revenue

Thor adds distribution and revenue

==> picture [37 x 44] intentionally omitted <==

7

• FY to date

Operations growth

1. Uscom Limited

Maintaining growth

1. Uscom UK

2. Uscom Budapest 4. Uscom Inc US

2 •• •[•]

[•][•] • •• • 3 • • • • •• • • • • •

4 • • ••

• • • • • • • • • • •

[•]

Key Markets 1. AsiaPAC – 65% 2/3. Europe – 27% 4. Nth America – 8%

• • •

==> picture [90 x 111] intentionally omitted <==

US Focus 2016 Stephen Wilson – Former VP Corporate Development Welch Allyn appointed

==> picture [16 x 14] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [37 x 44] intentionally omitted <==

8

Strategic growth

Complementary products and technology

Fluid, Sepsis

Hypertension & Vascular Health

& Heart Failure

• US 1.3bn market[ * ]

• US 1.7bn market[ *]

• CAGR of 7.6%[ * ]

• CAGR of 11.5%[ * ]

• CE, FDA, TGA, CFDA

• CE, FDA, TGA

USCOM 1A

BP+

Cardiac Output Monitoring Blood Pressure Monitoring

==> picture [176 x 181] intentionally omitted <==

==> picture [122 x 124] intentionally omitted <==

Acquired July 2013 Aus competitor - $50m

COPD

& Asthma

• US 400m market[ *]

• CAGR of 6.5%[ * ]

• CE, TGA, FDA

Thor

Pulmonary Monitoring

==> picture [162 x 99] intentionally omitted <==

Acquired August 2015

==> picture [37 x 44] intentionally omitted <==

9

• Source: MedTech Insight; Transparency Market Research

==> picture [206 x 128] intentionally omitted <==

New Acquisition

==> picture [204 x 85] intentionally omitted <==

==> picture [159 x 100] intentionally omitted <==

Uscom has acquired 100% of Thor Laboratories - Asthma

*

Company Overview

Uscom benefits

• High fidelity digital Doppler spirometry devices

• Cash flow positive, revenue of $500k

• Established manufacturing - 15 years

• Accredited international manufacturing

• Global reach

• 4 + 3 products, CE, FDA, TGA approvals

• Reimbursement in multiple markets

• Global distribution

• Strong R&D and grant history

• Technical R&D team 12 engineers

• Partners in Home Care Asthma in the USA

• Marketing and management

Synergy of science, operations and strategy

==> picture [37 x 44] intentionally omitted <==

10

• Agreement subject to DD and Uscom capital raise

Aus competitor $75m

New Products - Asthma

==> picture [71 x 95] intentionally omitted <==

Products in Market

New Products

Digital Doppler Spirometer

New – AsthmaHero

Drug delivery measure Telemetry to iPhone app Smart spacer Patient interactive

Home use

==> picture [145 x 131] intentionally omitted <==

==> picture [129 x 82] intentionally omitted <==

With Diagnostics and WIFI

Digital wifi spirometer

==> picture [128 x 100] intentionally omitted <==

New - BreatheSmart

Digital wifi spirometer Remote clinical monitoring Cloud diagnosis

Professional System

Desktop with advanced software analytics

==> picture [182 x 115] intentionally omitted <==

==> picture [181 x 103] intentionally omitted <==

New - Whistler

Neonatal Asthma diagnostic

==> picture [37 x 44] intentionally omitted <==

11

Revenue Growth Targets

==> picture [665 x 413] intentionally omitted <==

----- Start of picture text -----

Thor
Total Revenue
20,000,000
18,000,000
16,000,000 BP+
14,000,000
12,000,000
Thor
$ 10,000,000
BP+
USCOM
8,000,000
USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
$20m revenue by 2020 - 5 year CAGR of 58%
----- End of picture text -----*

$20m revenue by 2020 - 5 year CAGR of 58%

12

The Future

Value Cascade

Completion of Capital Raise Products USCOM 1A Uscom BP+ Spirotube Otthon S roDesk BreatheSmart AsthmaHero ThorSoft	Completion of Capital Raise Products USCOM 1A Uscom BP+ Spirotube Otthon S roDesk BreatheSmart AsthmaHero ThorSoft	Completion of Capital Raise Products USCOM 1A Uscom BP+ Spirotube Otthon S roDesk BreatheSmart AsthmaHero ThorSoft		Sales	Sales	Sales		Operations	Operations	Operations		Options Dividend Share price growth Transaction	Options Dividend Share price growth Transaction
	Completion of Capital Raise USCOM 1A Uscom BP+ Spirotube Otthon S roDesk BreatheSmart AsthmaHero ThorSoft				Current distribution Thor distribution New distribution Major partners				Global operations Revenue growth Profitability				Dividend Share price growth Transaction

Products – Sales – Revenue - Opportunities

==> picture [37 x 44] intentionally omitted <==

13

Business Risks & Mitigants

 Global markets unpredictable  Thor integration & key staff retention  Ongoing Thor business management  Competitiveness of market sectors  Thor distraction from USCOM & BP+  Regulatory costs and timelines  Distribution & revenue growth  Working capital requirements to meet increased product demand Risks		 Diversified and expanded products  Earn outs in Thor deal structure  Earn outs in Thor deal structure  Senior sales and marketing personell  Product diversification  Resources focussed on integration  Key Uscom and Thor staff  Senior sales and marketing resource  Additional WC in capital raise Mitigants

==> picture [37 x 44] intentionally omitted <==

14

UCM Investment

ASX 10yr CAGR

14 12 10 8 % 6 4 2 0 Mining Financials Health BHP NAB Resmed -2

UCM sales growth 2014 – 67% 2015 – 59%

Health outperforms!

==> picture [37 x 44] intentionally omitted <==

15

• Dividend exclusive

Market anomaly - opportunity

Opposing forces! Disconnect between performance and price

UCM share price

UCM Revenue and Income

==> picture [326 x 219] intentionally omitted <==

----- Start of picture text -----

$4,000,000
$3,500,000
$3,500,000
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,377,716
$1,500,000
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015 2016
----- End of picture text -----*

Unrecognised value

==> picture [37 x 44] intentionally omitted <==

16

• Estimate

Uscom

Under valued ✓ Strong growth phase ✓ ✓ Positioned for on going growth Strong underlying business ✓ Premium global markets ✓ Lifesaving technologies ✓ Sector leading management ✓ Aggressive global growth strategy ✓ Right time/value investment ✓

==> picture [37 x 44] intentionally omitted <==

17

==> picture [88 x 98] intentionally omitted <==

Proactive Investors

September 2015

Uscom (UCM) – Medical Devices and Revenue Growth

Thanks

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO